Verona Secures Approval from England and Wales High Court for Merck Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Acquisition Approval: Verona Pharma has received approval from the High Court of Justice of England and Wales for its acquisition by Merck, valued at approximately $10 billion.
Transaction Details: The acquisition involves Merck purchasing Verona Pharma for $107 per American Depositary Share (ADS), with the transaction expected to close following a court order delivery on October 7.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
